Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL

Retrospective Study of the Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07433400

Acronym

EVOLALPh1

Enrollment

500

Registered

2026-02-25

Start date

2025-08-29

Completion date

2035-12-31

Last updated

2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ph Positive ALL

Keywords

1ST RELAPSE OR MORE, TKI

Brief summary

The objective of this retrospective study is to examine the outcome of patients who relapse with Ph+ ALL and to potentially identify response profiles in order toadvance the treatment regimens that can be offered.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>= 18 * Relapse or refractory Ph1 ALL

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
Long term survival	5 years

Secondary

Measure	Time frame	Description
10 year-survival	10 years	—
Molecular response (BCR::ABL1 ratio)	At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse	Molecular response is assessed using BCR::ABL1 ratio, on bone marrow if available (if not, on blood)
Hematologic response	At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse	Hematologic response is defined by less than 5% of blasts on bone marrow aspiration
Death date	Up to 10 years	—
Cause of death	Up to 10 years	Cause of death can be : 1)disease, 2)complications related to treatment except bone marrow transplant, 3)Hematopoietic Stem Cells Transplantation related, 4)other
Treatment characteristics (treatment name)	At day 1 of each new treatment of relapse	Name of chemotherapy or immunotherapy used
Treatment characteristics (treatment dates)	At day 1 and at the end of each line of treatment of relapse	Start date and end date of treatment
Treatment characteristics (dose)	At day 1 of each new treatment of relapse	Dose of each treatment

Countries

France

Contacts

CONTACTAline SCHMIDT, MD/PhD

alschmidt@chu-angers.fr241354482

CONTACTVéronique LHERITIER, Central coordination

veronique.lheritier@chu-lyon.fr0478862239

Outcome results